EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Benchmark Response ( BMR ) Values for In Vivo Mutagenicity Endpoints

Paul A White, Guangchao Chen, Nikolai Chepelev, Madison A Bell, Lauren R Gallant, George E Johnson iD, Andreas Zeller iD, Marc A Beal, Alexandra S Long

Environmental and Molecular Mutagenesis · 2025

DOI: 10.1002/em.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Environmental and Molecular Mutagenesis, 2025. Verfasst von Paul A White und 8 weiteren Autor:innen. Beteiligte Einrichtung: Environmental Health Science and Research Bureau, Environmental and Radiation Health Sciences Directorate, Health Canada, Ottawa, Canada. Hauptthemen laut MEDLINE: Benchmarking, Mutagens, Endpoint Determination. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rijksinstituut voor Volksgezondheid en Milieu, Health Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The benchmark dose (BMD) approach constitutes the most effective and pragmatic strategy for the derivation of a point of departure (PoD) for comparative potency analysis, risk assessment, and regulatory decision‐making. There is considerable controversy regarding the most appropriate benchmark response (BMR) for genotoxicity endpoints. This work employed the Slob (2017) Effect Size (ES) theory to define robust BMR values for the in vivo transgenic rodent (TGR) and Pig‐a mutagenicity endpoints. An extensive database of dose–response data was prepared and curated; BMD analyses were used to determine endpoint‐specific maxima (i.e., parameter c ) and within‐group variance (i.e., var ). Detailed analyses investigated the dependence of var on experimental factors such as tissue, administration route, treatment duration, and post‐exposure tissue sampling time. The overall lack of influence of these experimental factors on var permitted the determination of typical values for the endpoints investigated. Typical var for the TGR endpoint is 0.19; the value for the Pig‐a endpoint is 0.29. Endpoint‐specific var values were used to calculate endpoint‐specific BMR values; the values are 47% for TGR and 60% for Pig‐a . Endpoint‐specific BMR values were also calculated using the trimmed distribution of study‐specific standard deviation (SD) values for concurrent controls. Those analyses yielded endpoint‐specific BMR values for the TGR and Pig‐a endpoints of 33% and 58%, respectively. Considering the results obtained, and the in vivo genetic toxicity BMR values noted in the literature, we recommend a BMR of 50% for in vivo mutagenicity endpoints. The value can be employed to interpret mutagenicity dose–response data in a risk assessment context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenchmarkingMutagensEndpoint DeterminationAnimalsMutagenicity TestsRisk AssessmentDose-Response Relationship, DrugAnimals, Genetically ModifiedMiceMembrane Proteins

Substanzen

Mutagensphosphatidylinositol glycan-class A proteinMembrane Proteins

Autor:innen und Institutionen

  • Environmental Health Science and Research Bureau, Environmental and Radiation Health Sciences Directorate, Health Canada, Ottawa, Canada.
  • Centre for Prevention, Lifestyle and Health, RIVM (National Institute for Public Health and the Environment), Bilthoven, the Netherlands.
  • Department of Biology, University of Ottawa, Ottawa, Canada.
  • Swansea University Medical School, Swansea University, Swansea, UK.
  • Pharmaceutical Sciences, pRED Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Bureau of Chemical Safety, Food and Nutrition Directorate, Health Canada, Ottawa, Canada.

ORCID-Profile: George E Johnson, Andreas Zeller

Förderung

  • Rijksinstituut voor Volksgezondheid en Milieu
  • Health Canada

Zitieren

APA

White, P. A., Chen, G., Chepelev, N., Bell, M. A., Gallant, L. R., Johnson, G. E., Zeller, A., Beal, M. A., & Long, A. S. (2025). Benchmark Response ( BMR ) Values for In Vivo Mutagenicity Endpoints. Environmental and Molecular Mutagenesis. https://doi.org/10.1002/em.70006

Vancouver

White PA, Chen G, Chepelev N, Bell MA, Gallant LR, Johnson GE, et al. Benchmark Response ( BMR ) Values for In Vivo Mutagenicity Endpoints. Environmental and Molecular Mutagenesis. 2025. doi:10.1002/em.70006

BibTeX
@article{White2025,
  author = {White, Paul A and Chen, Guangchao and Chepelev, Nikolai and Bell, Madison A and Gallant, Lauren R and Johnson, George E and Zeller, Andreas and Beal, Marc A and Long, Alexandra S},
  title = {Benchmark Response ( BMR ) Values for In Vivo Mutagenicity Endpoints},
  journal = {Environmental and Molecular Mutagenesis},
  year = {2025},
  doi = {10.1002/em.70006}
}
Kostenlos starten →